Liver Transplant CGM

Recruiting

• Conditions: Liver Transplant; Post Transplant Diabetes; Type 2 Diabetes

• Registration Number: NCT07216508
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.

Detailed Description

Liver transplant participants will be recruited. Participants will wear a blinded sensor after hospital discharge for up to 30 days. Data can be shared with participant and the providers retrospectively. Participants will be invited to wear another blinded sensor at 6 and 12 months.

Study Timeline

• Status Verified: 2025-10
• Study Start: 2025-10-01
• Study First Submitted: 2025-10-09
• Study First Submitted QC: 2025-10-09
• Last Update Submitted: 2025-10-09
• Study First Posted: 2025-10-14
• Last Update Posted: 2025-10-14
• Primary Completion: 2026-10-05
• Study Completion: 2027-10-05

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• inpatient liver transplant participants who have had an inpatient glucose greater than 180mg/dL

Exclusion Criteria

• having a planned discharge to a rehabilitation or nursing facility,
• a contraindication to sensor placement,
• if discharge is anticipated to be >30 days post-transplant, or
• if recent transplant also included a kidney or pancreas transplant

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time in range	28 days	Time in range 70-180mg/dL

Secondary Outcome Measures

Name	Time	Method
Percent time >180mg/dL	28 days	Percent time \>180mg/dL
Percent time >250mg/dL	28 days	Percent time \>250mg/dL
Percent time <70mg/dL	28 days	Percent time \<70mg/dL
Percent time <54mg/dL	28 days	Percent time \<54mg/dL
Transplant outcomes	1 year	Rate and time to of wound complications, vascular complications, biliary complications, acute kidney injury, transplant rejection, and readmissions

Trial Locations

Locations (1)

Mount Sinai Hospital; 🇺🇸 New York, New York, United States